within Pharmacolibrary.Drugs.ATC.V;

model V03AC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.16 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Deferiprone is an oral iron chelator primarily used for the treatment of iron overload in patients with thalassemia major and other chronic anemias, especially when standard chelation therapy is inadequate or contraindicated. It is approved and in use for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported from studies in adult patients (both sexes) with thalassemia major receiving oral deferiprone under steady-state conditions.</p><h4>References</h4><ol><li><p>Bellanti, F, et al., &amp; Della Pasqua, O (2014). Population pharmacokinetics of deferiprone in healthy subjects. <i>British journal of clinical pharmacology</i> 78(6) 1397–1406. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12473&quot;>10.1111/bcp.12473</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25052529/&quot;>https://pubmed.ncbi.nlm.nih.gov/25052529</a></p></li><li><p>al-Refaie, FN, et al., &amp; Hoffbrand, AV (1995). Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. <i>British journal of haematology</i> 89(2) 403–408. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2141.1995.tb03318.x&quot;>10.1111/j.1365-2141.1995.tb03318.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7873392/&quot;>https://pubmed.ncbi.nlm.nih.gov/7873392</a></p></li><li><p>Fassos, FF, et al., &amp; Koren, G (1996). The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. <i>International journal of clinical pharmacology and therapeutics</i> 34(7) 288–292. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8832304/&quot;>https://pubmed.ncbi.nlm.nih.gov/8832304</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AC02;
